The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.
M. Gnant
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Honoraria - Amgen; AstraZeneca; Novartis; Pfizer; Roche; Sanofi ; Schering-Plough
Research Funding - AstraZeneca; Novartis; Pfizer
B. Mlineritsch
Honoraria - AstraZeneca; Cephalon; Novartis; Pfizer; Roche; Sanofi
H. Stoeger
Honoraria - GlaxoSmithKline; Novartis; Roche; Sanofi
G. Luschin-Ebengreuth
Honoraria - AstraZeneca; Novartis
S. Poestlberger
Honoraria - AstraZeneca; Novartis
P. C. Dubsky
Honoraria - AstraZeneca; Novartis
R. Jakesz
Consultant or Advisory Role - AstraZeneca; Roche; Sanofi
Honoraria - AstraZeneca; Roche; Sanofi
C. F. Singer
Honoraria - AstraZeneca; Novartis
Research Funding - Amgen
H. Eidtmann
Honoraria - AstraZeneca; Novartis
R. Greil
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca; Novartis